Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12874139 | 0.97 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL27711717 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL1626512 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL27711718 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| Ammonia Solution, Strong SCHEMBL27780858 | 0.85 | ALDH1A1 (0.43) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| Ammonia Solution, Strong SCHEMBL27493617 | 0.85 | ALDH1A1 (0.43) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL27542759 | 0.84 | ALDH1A1 (0.42) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL27827638 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL27696911 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL30975317 | 0.81 | LTA4H (0.44) | ALDH1A1MAPK1L3MBTL1SYKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| EP-2539364-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2013-01-02 | — | — | EP | disclosed |
| US-20120021973-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | US | disclosed |
| EP-2370104-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011104378-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | WO | disclosed |
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
| WO-2010060901-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021973-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | ALDH1A1 4086/4885MAPK1 1616/4885L3MBTL1 2082/4885 |
| US-20100173835-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | ALDH1A1 4086/4885MAPK1 1616/4885L3MBTL1 2082/4885 |
| US-20130012432-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | ALDH1A1 4086/4885MAPK1 1616/4885L3MBTL1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.